Archive | European Approval

Once Monthly Opdivo Use Approved in EU for Certain Melanoma, Renal Cell Cancer Patients

The European Commission has approved a new dosing schedule for Opdivo(nivolumab), allowing the PD-1 inhibitor to be given every four weeks to patients with advanced melanoma and those with previously treated renal cell carcinoma.

Read the full story

Posted in Melanoma In The News, European Approval

Europe Approves New Nivolumab Dosing Schedules

A 4-week dosing schedule for nivolumab (Opdivo) has been approved by the European Commission for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC), Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor, has announced.

Read the full story

Posted in Melanoma In The News, European Approval

European Panel Backs New Nivolumab Dosing Schedules

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended adding the option of a 4-week dosing schedule to the label for nivolumab (Opdivo) for the treatment of patients with advanced melanoma and previously treated renal cell carcinoma (RCC).1

Read the full story

Posted in Melanoma In The News, European Approval

Ipilimumab Approved in Europe for Pediatric Melanoma

Ipilimumab (Yervoy) has been approved by the European Commission for the treatment of patients aged 12 and older with unresectable or metastatic melanoma.

Read the full story

Posted in Melanoma In The News, European Approval, Information

Melanoma Google Alerts

Melanoma Google Alerts is a summary of daily articles found in print and on the internet. The articles do not necessarily represent the views of Melbourne Melanoma Project

News Archives

News Categories